Hadassah

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

Monday, Oct 24 2011

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

BreathID, a noninvasive early diagnosis device for acute liver failure developed at the Hadassah University Medical Center, has obtained a United States Food and Drug Administration (FDA) Humanitarian Device Exemption, which provides a fast-track toward approval. Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine A is Medical Director of BreathID's developer, Exalenz Bioscience Ltd., a startup company of Hadasit, Hadassah's technology transfer arm.

The device, as well as saving lives through early diagnosis, can lead to the elimination of unnecessary liver transplants. The humanitarian use device (HUD) designation which BreathID received means that the device does not have to undergo an efficacy trial, thereby greatly shortening the approval process if it meets FDA requirements. BreathID's effectiveness in diagnosing acute liver failure was demonstrated in a trial of several dozen patients at Hadassah and London's Kings College.
The FDA has already approved a clinical trial of the BreathID device for the early diagnosis of Hepatocellular Carcinoma, a liver cancer.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Oct 22 2018

Hadassah Ophthalmology Department: An Environment That Encourages Insight

Throughout the past 100 years, the Hadassah Medical Organization’s Department of Ophthalmology has prioritized a platform that encourages and nurtures the development of new insights into eye diseases and the creation of new therapies, says Prof. Itay Chowers, the department’s new director.

READ MORE ›
alt_text

Thursday, Oct 18 2018

Advocacy Update | Advocate for Breast Cancer Month

At Hadassah, we're using three proven strategies to fight breast cancer: education & awareness, domestic advocacy, and support for groundbreaking research at the Hadassah Medical Organization (HMO).

READ MORE ›
alt_text

Monday, Oct 15 2018

Hadassah Dedicates Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem

Hadassah unveiled the Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem on Friday, October 12th in Jerusalem, announced Ellen Hershkin, National President, Hadassah, the Women’s Zionist Organization of America, Inc.

READ MORE ›
alt_text

Monday, Oct 15 2018

Hadassah Dedicates Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem News Release

Hadassah unveiled the Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem on Friday, October 12th in Jerusalem, announced Ellen Hershkin, National President, Hadassah, the Women’s Zionist Organization of America, Inc.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More